Arformoterol

Arformoterol
Clinical data
Trade names Brovana
AHFS/Drugs.com Monograph
MedlinePlus a602023
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Inhalation solution for nebuliser
ATC code none
Legal status
Legal status
Pharmacokinetic data
Protein binding 52–65%
Biological half-life 26 hours
Identifiers
CAS Number 67346-49-0 YesY
PubChem (CID) 3083544
IUPHAR/BPS 7479
DrugBank DB01274 YesY
ChemSpider 2340731 YesY
UNII F91H02EBWT YesY
ChEBI CHEBI:408174 YesY
ChEMBL CHEMBL1201137 N
Chemical and physical data
Formula C19H24N2O4
Molar mass 344.405 g/mol
 NYesY (what is this?)  (verify)

Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]

It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

References

  1. "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14.

External links

This article is issued from Wikipedia - version of the 9/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.